Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Proposed Fundraising

3 Aug 2017 12:00

RNS Number : 0463N
Byotrol PLC
03 August 2017
 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL ("RESTRICTED JURISDICTION"). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES DISCUSSED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SINGAPORE OR THE REPUBLIC OF SOUTH AFRICA.

 

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN BYOTROL PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

3 August 2017

 

Byotrol plc

 

Confirmation of oversubscribed £4.3 million fundraise subject to shareholder approval

 

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that, following the announcement of earlier today, the Company has raised a total of £4.3 million (before expenses) with new and existing investors of 103,787,000 Placing Shares and 3,000,000 Subscription Shares at a price of 4 pence per share.

John Langlands, Chairman of Byotrol, has agreed to subscribe for 2,500,000 Subscription Shares as part of the Subscription. Mr. Langlands is a related party of the Company for the purposes of the AIM Rules by virtue of his status as a Director of the Company. The independent directors for this purpose (being all Directors except for Mr. Langlands), consider, having consulted with the Company's nominated adviser, finnCap, that the terms of the Subscription in regards to Mr. Langlands is fair and reasonable insofar as the Company's Shareholders are concerned.

Pursuant to a Convertible Loan Note Instrument, the Company issued £380,000 loan notes to a number of Directors, former directors and certain other investors in 2013. It has now been resolved to redeem all of the Convertible Loan Notes and has today issued notices specifying a date of redemption of 1 September 2017. Holders of Convertible Loan Notes may elect to convert their Convertible Loan Notes into shares at a conversion price of 3.7p per new Ordinary Share at any time up to 25 August 2017. Trevor Francis and Till Medinger, each currently holding £40,000 of Convertible Loan Notes, have indicated they will convert their Convertible Loan Notes into Ordinary Shares. The Convertible Loan Notes have a coupon on 10 per cent.

The Fundraising is subject to the passing of the Resolutions at the General Meeting. Shareholder approval in respect of the Fundraising will be sought at the General Meeting which is being convened for 11 a.m. on 4 September 2017 at the offices of finnCap Ltd at 60 New Broad Street, London EC2M 1JJ. Provided that the Resolutions are passed and the Fundraising has otherwise become unconditional, completion of the Fundraising is expected to take place on 5 September 2017.

A Circular and a Notice of General Meeting will be posted to Shareholders shortly and will be available shortly on Byotrol's website, www.byotrol.co.uk

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released earlier today unless the context requires otherwise.

David Traynor, CEO of Byotrol, commented:

"We are delighted to have received such strong support from both existing and several significant new shareholders for this oversubscribed fundraising. The funding will allow the Board to capitalise on the substantial opportunities identified through our three core technologies. We will use these funds to fully resource an effective sales and marketing team in order to accelerate the Company's growth."

Contacts:

Byotrol plc 01925 742 000

David Traynor - Chief Executive

finnCap Ltd 020 7220 050(Nominated Adviser & Broker)

Geoff Nash/Carl Holmes/James Thompson - Corporate Finance

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUOVRRBNAWRAR
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.